FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2027293933> ?p ?o ?g. }

• W2027293933 endingPage "913" @default.
• W2027293933 startingPage "911" @default.
• W2027293933 abstract "ImmunotherapyVol. 5, No. 9 EditorialThe virtues and vices of harnessing HSV vectors for CNS autoimmunity modulationVeijo Hukkanen & Michaela NygårdasVeijo Hukkanen* Author for correspondenceDepartment of Virology, University of Turku, Kiinamyllynkatu 13, FIN-20520, Turku, Finland. Search for more papers by this authorEmail the corresponding author at veijo.hukkanen@utu.fi & Michaela NygårdasDepartment of Virology, University of Turku, Kiinamyllynkatu 13, FIN-20520, Turku, FinlandSearch for more papers by this authorPublished Online:2 Sep 2013https://doi.org/10.2217/imt.13.100AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: autoimmunityautoimmune encephalomyelitiscytokinegene therapyHSVmultiple sclerosisvectorReferences1 Manservigi R, Argnani R, Marconi P. HSV recombinant vectors for gene therapy. Open Virol. J.4,123–156 (2010).Medline, CAS, Google Scholar2 Goins WF, Cohen JB, Glorioso JC. Gene therapy for the treatment of chronic peripheral nervous system pain. Neurobiol. Dis.48(2),255–270 (2012).Crossref, Medline, CAS, Google Scholar3 Cassady KA, Parker JN. Herpesvirus vectors for therapy of brain tumors. Open Virol. J.4,103–108 (2010).Medline, CAS, Google Scholar4 Senzer NN, Kaufman HL, Amatruda T et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol.27(34),5763–5771 (2009).Crossref, Medline, CAS, Google Scholar5 Epstein AL. Progress and prospects: biological properties and technological advances of herpes simplex virus type 1-based amplicon vectors. Gene Ther.16(6),709–715 (2009).Crossref, Medline, CAS, Google Scholar6 Shayakhmetov DM, Di Paolo NC, Mossman KL. Recognition of virus infection and innate host responses to viral gene therapy vectors. Mol. Ther.18(8),1422–1429 (2010).Crossref, Medline, CAS, Google Scholar7 Hukkanen V, Paavilainen H, Mattila RK. Host responses to herpes simplex virus and herpes simplex virus vectors. Future Virol.5(4),493–512 (2010).Link, CAS, Google Scholar8 Tsitoura E, Epstein AL. Constitutive and inducible innate responses in cells infected by HSV-1-derived amplicon vectors. Open Virol. J.4,96–102 (2010).Medline, CAS, Google Scholar9 Furlan R, Poliani P, Galbiati F et al. Central nervous system delivery of interleukin 4 by a nonreplicative herpes simplex type 1 viral vector ameliorates autoimmune demyelination. Hum. Gene Ther.9,2605–2617 (1998).Crossref, Medline, CAS, Google Scholar10 Furlan R, Poliani P, Marconi P et al. Central nervous system gene therapy with interleukin-4 inhibits progression of ongoing relapsing-remitting autoimmune encephalomyelitis in Biozzi AB/H mice. Gene Ther.8,13–19 (2001).Crossref, Medline, CAS, Google Scholar11 Broberg E, Setala N, Roytta M et al. Expression of interleukin-4 but not of interleukin-10 from a replicative herpes simplex virus type 1 viral vector precludes experimental allergic encephalomyelitis. Gene Ther.8(10),769–777 (2001).Crossref, Medline, CAS, Google Scholar12 Nygardas M, Aspelin C, Paavilainen H, Roytta M, Waris M, Hukkanen V. Treatment of experimental autoimmune encephalomyelitis in SJL/J mice with a replicative HSV-1 vector expressing interleukin-5. Gene Ther.18(7),646–655 (2011).Crossref, Medline, CAS, Google Scholar13 Furlan R, Bergami A, Brambilla E et al. HSV-1-mediated IL-1 receptor antagonist gene therapy ameliorates MOG(35–55)-induced experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Ther.14(1),93–98 (2007).Crossref, Medline, CAS, Google Scholar14 Furlan R, Brambilla E, Ruffini F et al. Intrathecal delivery of IFN-γ protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J. Immunol.167(3),1821–1829 (2001).Crossref, Medline, CAS, Google Scholar15 Zandian M, Mott KR, Allen SJ, Dumitrascu O, Kuo Jz, Ghiasi H. Use of cytokine immunotherapy to block CNS demyelination induced by a recombinant HSV-1 expressing IL-2. Gene Ther.18(7),734–742 (2011).Crossref, Medline, CAS, Google Scholar16 Ruffini F, Furlan R, Poliani P et al. Fibroblast growth factor-II gene therapy reverts the clinical course and the pathological signs of chronic experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Ther.8,1207–1213 (2001).Crossref, Medline, CAS, Google Scholar17 Nygardas M, Paavilainen H, Muther N et al. A herpes simplex virus-derived replicative vector expressing LIF limits experimental demyelinating disease and modulates autoimmunity. PLoS ONE8(5),e64200 (2013).Crossref, Medline, CAS, Google Scholar18 Jiang Y, Wei N, Zhu J et al. A new approach with less damage: intranasal delivery of tetracycline-inducible replication-defective herpes simplex virus type-1 vector to brain. Neuroscience201,96–104 (2012).Crossref, Medline, CAS, Google Scholar19 Broberg EK, Peltoniemi J, Nygardas M, Vahlberg T, Roytta M, Hukkanen V. Spread and replication of and immune response to gamma134.5-negative herpes simplex virus type 1 vectors in BALB/c mice. J. Virol.78(23),13139–13152 (2004).Crossref, Medline, CAS, Google Scholar20 Peltoniemi J, Broberg EK, Nygardas M, Eralinna JP, Waris M, Hukkanen V. Enhancement of Th2 responses to replicative herpes simplex virus type 1 vectors by immunomodulative chemotherapy. Int. Immunopharmacol.6(5),817–829 (2006).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByThe In Vitro Replication, Spread, and Oncolytic Potential of Finnish Circulating Strains of Herpes Simplex Virus Type 113 June 2022 | Viruses, Vol. 14, No. 6 Vol. 5, No. 9 Follow us on social media for the latest updates Metrics Downloaded 31 times History Published online 2 September 2013 Published in print September 2013 Information© Future Medicine LtdKeywordsautoimmunityautoimmune encephalomyelitiscytokinegene therapyHSVmultiple sclerosisvectorFinancial & competing interests disclosureFinancial support from the Academy of Finland is acknowledged (grant #128915 and 259725). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download" @default.
• W2027293933 created "2016-06-24" @default.
• W2027293933 creator A5008462818 @default.
• W2027293933 creator A5012933488 @default.
• W2027293933 date "2013-09-01" @default.
• W2027293933 modified "2023-09-27" @default.
• W2027293933 title "The virtues and vices of harnessing HSV vectors for CNS autoimmunity modulation" @default.
• W2027293933 cites W1589597578 @default.
• W2027293933 cites W1970620921 @default.
• W2027293933 cites W1975711421 @default.
• W2027293933 cites W1992897696 @default.
• W2027293933 cites W2004747749 @default.
• W2027293933 cites W2005874157 @default.
• W2027293933 cites W2022499749 @default.
• W2027293933 cites W2038821785 @default.
• W2027293933 cites W2046025234 @default.
• W2027293933 cites W2046075544 @default.
• W2027293933 cites W2079623756 @default.
• W2027293933 cites W2082150850 @default.
• W2027293933 cites W2135912768 @default.
• W2027293933 cites W2171638071 @default.
• W2027293933 cites W2323125095 @default.
• W2027293933 cites W2328332609 @default.
• W2027293933 cites W2332629879 @default.
• W2027293933 doi "https://doi.org/10.2217/imt.13.100" @default.
• W2027293933 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23998724" @default.
• W2027293933 hasPublicationYear "2013" @default.
• W2027293933 type Work @default.
• W2027293933 sameAs 2027293933 @default.
• W2027293933 citedByCount "1" @default.
• W2027293933 countsByYear W20272939332022 @default.
• W2027293933 crossrefType "journal-article" @default.
• W2027293933 hasAuthorship W2027293933A5008462818 @default.
• W2027293933 hasAuthorship W2027293933A5012933488 @default.
• W2027293933 hasConcept C159047783 @default.
• W2027293933 hasConcept C2522874641 @default.
• W2027293933 hasConcept C2779473830 @default.
• W2027293933 hasConcept C2781196997 @default.
• W2027293933 hasConcept C55493867 @default.
• W2027293933 hasConcept C71924100 @default.
• W2027293933 hasConcept C82210918 @default.
• W2027293933 hasConcept C86803240 @default.
• W2027293933 hasConceptScore W2027293933C159047783 @default.
• W2027293933 hasConceptScore W2027293933C2522874641 @default.
• W2027293933 hasConceptScore W2027293933C2779473830 @default.
• W2027293933 hasConceptScore W2027293933C2781196997 @default.
• W2027293933 hasConceptScore W2027293933C55493867 @default.
• W2027293933 hasConceptScore W2027293933C71924100 @default.
• W2027293933 hasConceptScore W2027293933C82210918 @default.
• W2027293933 hasConceptScore W2027293933C86803240 @default.
• W2027293933 hasIssue "9" @default.
• W2027293933 hasLocation W20272939331 @default.
• W2027293933 hasLocation W20272939332 @default.
• W2027293933 hasOpenAccess W2027293933 @default.
• W2027293933 hasPrimaryLocation W20272939331 @default.
• W2027293933 hasRelatedWork W1425291984 @default.
• W2027293933 hasRelatedWork W1645018133 @default.
• W2027293933 hasRelatedWork W198294540 @default.
• W2027293933 hasRelatedWork W1993339219 @default.
• W2027293933 hasRelatedWork W2013208424 @default.
• W2027293933 hasRelatedWork W2030010353 @default.
• W2027293933 hasRelatedWork W2038801503 @default.
• W2027293933 hasRelatedWork W2066091494 @default.
• W2027293933 hasRelatedWork W2196865580 @default.
• W2027293933 hasRelatedWork W2563064067 @default.
• W2027293933 hasVolume "5" @default.
• W2027293933 isParatext "false" @default.
• W2027293933 isRetracted "false" @default.
• W2027293933 magId "2027293933" @default.
• W2027293933 workType "article" @default.